Subject: GS 2: Polity and Governance
Context: Recently, the Union Health Ministry has banned 16 Fixed-Dose Combination (FDC) drugs including common pain relievers, skin creams, and stomach ache medicines.
- The action was taken under Section 26A of the Drugs and Cosmetics Act, 1940, which empowers the government to prohibit drugs in public interest when they are found unsafe, ineffective or irrational.
- Government expert panels found these drug mixes to be “irrational, unsafe, or lacking any real medical logic.” This move highlights how the government steps in to protect public health from unsafe medicines.
UPSC Coaching Classes
About Fixed-Dose Combinations (FDCs)
- Fixed-Dose Combinations (FDCs) are pharmaceutical products that contain two or more active pharmaceutical ingredients (APIs) combined in a single dosage form in a fixed ratio. These products are common in everyday healthcare and include widely used medications such as:
- Common pain relievers and cold formulas.
- Oral anti-diabetic drugs to manage blood sugar.
- Daily nutritional supplements and multivitamins.
Classification of FDCs
India’s drug regulatory framework, under the Central Drugs Standard Control Organisation (CDSCO), classifies FDCs into four groups based on the nature of the combination and the level of regulatory scrutiny required:
- Group I: FDCs containing new drugs — These include combinations where one or more active ingredients is a new chemical entity.
- Such FDCs are treated as “New Drugs” under the NDCT Rules, 2019 and require comprehensive clinical trial data similar to that for a new single drug molecule.
- Group II: First-time combinations of approved drugs — These cover combinations of already approved or marketed individual drugs being combined for the first time, particularly where pharmacodynamic or pharmacokinetic interactions are possible.
- Additional clinical data is usually required to establish safety and efficacy.
- Group III: Already marketed FDCs with changed ratio or new claim — These include existing FDCs where the manufacturer proposes a change in the ratio of ingredients or introduces a new therapeutic claim.
- Supporting safety and efficacy data must be provided.
- Group IV: Convenience-based combinations of widely used drugs — These are combinations of well-established drugs that have been widely used for years for the same indication, where concomitant use is common and the primary benefit is patient convenience.
- These generally require minimal additional clinical data if stability and low interaction risk are demonstrated.
Significance of FDCs
Fixed-Dose Combinations play a vital role in India’s healthcare system, especially for managing chronic diseases:
- Improved Patient Compliance and Adherence: By combining multiple drugs into a single dosage form, FDCs reduce the pill burden, making treatment regimens simpler and improving adherence, particularly in chronic diseases.
- Enhanced Therapeutic Effectiveness: FDCs often provide synergistic therapeutic effects, where drugs with complementary mechanisms of action work together to achieve better clinical outcomes than individual medicines.
- Cost-Effective Treatment: Combining medicines into a single formulation lowers manufacturing, packaging, and distribution costs, making long-term treatment for conditions such as diabetes, hypertension, and infections more affordable.
- Public Health Utility: FDCs simplify treatment protocols and support large-scale healthcare delivery, making them valuable in national health programmes and resource-constrained settings.
About the Central Drugs Standard Control Organisation (CDSCO)
The central watchdog for medicine safety in India is the Central Drugs Standard Control Organisation (CDSCO).
- Status: It serves as India’s National Regulatory Authority (NRA) under the Directorate General of Health Services, operating within the Ministry of Health & Family Welfare.
- Headquarters: New Delhi
- Key Responsibilities of CDSCO:
- Safety and Quality Assurance: It is mandated to maintain absolute transparency, accountability, and uniformity across the country to secure the safety, effectiveness, and quality of medical products.
- Approval of New Drugs: It acts as the gatekeeper for the Indian market by approving new drug molecules and rigorously overseeing all human clinical trials.
- Setting Standards: It establishes national quality standards for drugs and strictly controls the quality of all imported medical formulations.
Collaboration with State Regulators:
India utilizes a joint regulatory structure where central and state regulators work closely together:
- Joint Licensing Framework: For highly sensitive, critical medical items, CDSCO does not act alone. Along with state authorities, it jointly grants manufacturing and distribution licenses for blood products, vaccines, IV fluids, and sera.
- Expert Guidance: CDSCO provides administrative direction and expert advice to state drug bodies to ensure uniform enforcement of the Drugs and Cosmetics Act across every state in the country.
|
Challenges Associated with FDCs
Despite their benefits, several issues persist with FDCs in India:
- Proliferation of Irrational Combinations: Many FDCs (especially in Groups II–IV) have been approved or marketed without sufficient scientific justification, leading to unnecessary drug exposure and hidden side effects.
- Difficulty in Identifying Causative Agents: Adverse reactions become harder to attribute to a specific ingredient, complicating pharmacovigilance and patient management.
- Antimicrobial Resistance (AMR): Irrational antibiotic FDCs contribute significantly to the emergence of superbugs by exposing bacteria to sub-optimal drug levels.
- Regulatory Coordination Gaps: Historical approvals by State Licensing Authorities without DCGI nod created a large pool of unapproved but marketed FDCs, highlighting weaknesses in centre-state regulatory coordination.
- Enforcement Issues: Weak post-marketing surveillance and industry pressure have delayed action against unsafe combinations.
Click to Know UPSC OnlyIAS Coaching Centres
Way Forward
To strengthen the governance of FDCs and protect public health, the following steps are essential:
- Periodic Scientific Review: Institutionalise regular review of all marketed FDCs by expert committees to weed out irrational combinations.
- Strengthened Centre-State Coordination: Ensure uniform enforcement of CDSCO guidelines across states and mandate prior DCGI approval for all new FDCs.
- Robust Pharmacovigilance: Expand adverse drug reaction monitoring and implement stricter post-marketing surveillance mechanisms.
- Promotion of Rational Use: Encourage evidence-based prescribing, awareness campaigns for doctors and patients, and integration of rational drug use in medical education.
- Alignment with Global Standards: Harmonise FDC regulation with WHO guidelines on Fixed-Dose Combinations and intensify efforts to combat AMR under the National Action Plan.
23 Jun 2026
